Clifford Stocks

Clifford Stocks has more than twenty-eight years of experience in the biotech industry and is the Founder and Chief Executive Officer of OncoResponse, Inc., a Seattle based immuno-oncology company formed as a broad strategic alliance with MD Anderson Cancer Center. Prior to OncoResponse, he served as Chief Executive Officer at Theraclone Sciences, where he was responsible for leading all aspects of the company’s efforts to discover and develop novel therapeutic antibody immunotherapies for the treatment of infectious disease including HIV-cure antibodies licensed to Gilead. Prior to Theraclone, Mr. Stocks served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in 2011. Mr. Stocks spent over 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing, and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks’ early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago. Mr. Stocks received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business, and a Bachelor of Science degree in biology from the University of Utah.